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Abstract: The polyene antibiotic Amphotericin B (AMB) is one of the ﬁ  rst therapeutic agents to 
be marketed commercially as nanosized formulations in which the drug is associated with lipids 
as liposomes or complexes. In this way, its renal toxicity is reduced and its therapeutic index 
improved. This review summarizes the particular properties of AMB which justify this type of 
formulation and the early work leading up to their development. The clinical results obtained 
in the treatment of fungal infections are reviewed and their activity against leishmaniasis is also 
evoked. Some newer formulations of AMB, based on both lipids and polymers are described. In 
particular, their potential by the oral and pulmonary routes are discussed. Finally, the develop-
ment of targeted systems to deliver the drug to speciﬁ  c cells and tissues is considered.
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Introduction
The polyene antibiotic Amphotericin B (AMB) is one of the ﬁ  rst therapeutic agents 
to be marketed commercially as nanosized formulations. This review will summarize 
the particular properties of AMB which justify this type of formulation and the early 
work leading up to their development. The clinical results obtained in the treatment 
of fungal infections will be reviewed. Finally, some newer formulations, in which the 
drug has been associated with polymers as well as lipids, and new directions in the 
use of AMB will be considered.
Properties of AMB and early work with AMB
in liposomes
Properties of AMB
The antimicrobial properties of AMB, a macrolide extracted from Streptomyces 
nodosus, were ﬁ  rst noted in the 1950s (Vandeputte et al 1955–1956) and the antibi-
otic arrived on the market in 1958 (Utz et al 1958–1959). The drug possesses a wide 
spectrum of activity, encompassing a large number of fungal species as well as pro-
tozoan parasites (Leishmania species) and amoebae (Naegleria species) (for a recent 
review, see Kleinberg 2006). More recently, it was found to have some activity against 
prion diseases (Hartsel and Weiland 2003; Mangé et al 2000). Despite its therapeutic 
importance, the physicochemical properties of AMB lead to some difﬁ  culties in its 
formulation and utilization, and solutions based on “nanotechnology” have been 
developed in response to these.
AMB (Figure 1) is an asymmetrical, cyclic molecule with one hydrophobic and 
one hydrophilic face, and an aminosugar (mycosamine) group. It has a very limited 
solubility proﬁ  le, being almost completely insoluble in water, sparingly soluble in 
alcohols and soluble in organic solvents such as DMSO and DMF (Brittain 1994). In 
water, AMB aggregates, forming ﬁ  rst dimers by apposition of two hydrophobic faces International Journal of Nanomedicine 2007:2(3) 302
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followed by larger aggregates (Mazerski et al 1982). This 
insolubility in aqueous media also leads to low bioavailabil-
ity of AMB by the oral route. Its use is therefore limited to 
intravenous infusion and local application. The conventional 
formulation of AMB (Fungizone®) is mixed micelles with 
the detergent sodium deoxycholate, and in this form it is 
the drug of choice for systemic infections with sensitive 
fungal species (Georgopapadakou and Walsh 1996). It 
is usually administered by slow perfusion diluted in 5% 
glucose. However, dose-limiting side-effects are frequent, 
the most severe being renal toxicity (Brezis et al 1984).
Both the therapeutic and toxic effects of AMB derive 
from its interaction with lipids, and in particular, mem-
brane sterols. The antibiotic can form complexes with both 
ergosterol, the principal sterol in fungal cell membranes, 
and cholesterol in mammalian cell membranes. The result 
of this is the formation of pores leading to the leakage of 
electrolytes and other cell components (De Kruijff and De-
mel 1974). The selectivity for fungal cell membranes is the 
result of greater afﬁ  nity for ergosterol than cholesterol, due 
to the presence of a double bond on carbon 22 in the former 
(Cybulska et al 1986).
Given the afﬁ  nity of the antibiotic for biological mem-
branes, incorporation of AMB into lipid-based nanosystems 
in order to improve its therapeutic index has been studied 
since the 1980s. Three of these systems are now commer-
cially available.
Mechanisms of action
In 1996, Hartsel and Bolard reviewed the mechanisms by 
which the selectivity of AMB towards fungal cells can be 
improved by association with lipid systems.  One mecha-
nism is related to the molecular state of the AMB when it 
is released from the formulation. It has been observed that 
while both monomeric and self-aggregated AMB associate 
with ergosterol, only self-aggregated AMB forms pores in 
cholesterol-containing membranes. It follows that a formula-
tion that can assure that AMB is released only as monomers 
will have an improved therapeutic index. On dilution in the 
plasma, AMB is rapidly released from Fungizone® in the 
aggregated form and toxicity to mammalian cells ensues. 
However, AMB can also bind to membrane phospholipids, 
so the relative afﬁ  nity for cell and drug delivery system lip-
ids may contribute to determining the reduction of toxicity. 
When AMB binds to cell membranes it has a pro-oxidative 
effect, and this may be as important as pore formation in 
generating cell damage (Bratjburg et al 1985).
Furthermore, the afﬁ  nity of AMB for lipids means that it 
is readily incorporated into plasma lipoproteins, particularly 
low density lipoprotein (Bratjburg et al 1984). Receptor-
mediated uptake of low density lipoprotein carrying AMB 
by renal epithelial cells is one mechanism of toxicity in 
this organ. Therefore, the rate of transfer between the drug 
delivery system and circulating lipoproteins will be another 
factor which determines the efﬁ  cacy of the system (Legrand 
et al 1996).
AMB also has effects on the immune system, and in 
particular can modulate the functions of macrophages. 
For example, it stimulates production of cytokines such as 
interleukin 1 (Chia and McManus 1990) and tumor necrosis 
factor alpha (TNF-α) (Tokuda et al 1993), reactive oxygen 
intermediates (Wilson et al 1991) and nitric oxide (NO) 
(Herrmann et al 1994; Mozaffarian et al 1997), as well as 
chemotaxis and phagocytosis. These properties could con-
tribute to the antimicrobial activity of AMB, but could also 
increase its toxicity, for example by causing fever and chills. 
Larabi et al (2001) compared the production of NO and TNF-
α induced in non infected mouse peritoneal macrophages 
by different lipid formulations of AMB compared with 
free AMB, in association with co-stimulants. At equivalent 
AMB concentration, mediator production was always less 
with the lipid formulations than with the free drug, and the 
liposomal forms (eg, AmBisome®) reduced this more than 
lipid complexes (eg, Abelcet®). In macrophages infected with 
Leishmania donovani, AMB also contributed to stimulating 
NO and TNF-α production, but the concentrations at which 
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Figure 1 Structure of Amphotericin B.International Journal of Nanomedicine 2007:2(3) 303
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this occurred were much higher than those causing parasite 
killing (Larabi et al unpublished results), suggesting that in 
this case at least, the immunostimulating effects contribute 
more to the side-effects of AMB than to its antiparasitic 
activity.
Early liposomal formulations
The ﬁ  rst study incorporating AMB into liposomes was 
performed by New et al in 1981. Their interest was in the 
antileishmanial properties of the antibiotic, and followed on 
from studies of encapsulated antimonial drugs. The fact that 
Leishmania parasites are located within phagocytic cells, and 
that liposomes are also preferentially accumulated by these 
cells made this approach particularly attractive (Heath et al 
1984). However, the main effect of the liposomal formulation 
was to reduce the toxicity of AMB, allowing higher doses 
to be administered and thus increasing “efﬁ  cacy”. Soon 
afterwards, similar results were obtained in infections with 
Cryptococcus (Graybill et al 1982) and in histoplasmosis 
(Taylor et al 1982). However, the antimicrobial activity of 
AMB per se was not increased by encapsulation. During this 
period, the inﬂ  uence of the liposome composition, and size, 
on the activity of AMB was studied. In one study (Lopez-
Berestein et al 1983), it was found that liposomes containing 
phospholipids alone were more efﬁ  cient than liposomes con-
taining sterols (cholesterol or ergosterol). One explanation 
for this could be that the strong binding of AMB to sterol 
prevents its release from the liposomes and its interaction 
with fungal cell membranes. A study by Szoka et al (1987) of 
a range of liposome sizes and compositions found that there 
was no correlation between the extent of reduction of toxic-
ity against mouse macrophages in vitro and the reduction of 
lethality in vivo. In vivo, small sterol-containing liposomes 
were less toxic than larger ones, and liposomes without 
sterol but containing phospholipids which were in a “solid” 
(liquid crystal) state at physiological temperatures were less 
toxic than ones in which the phospholipids were in a ﬂ  uid 
state. A large number of different AMB formulations were 
tested, leading to the commercialization of three of them. 
These have quite different physico-chemical structures (see 
below), but all reduce the toxicity of AMB compared with 
Fungizone®.
Commercial formulations of AMB
Three lipid-based formulations of AMB are at present 
licensed for clinical use. Their physico-chemical properties 
are listed in Table 1.
Physico-chemical properties
AmBisome® is the only true liposomal formulation of the 
three. It is composed of small, unilamellar vesicles composed 
of lipids which yield a very stable bilayer, in the gel state 
at physiological temperature. AMB is incorporated into this 
bilayer at 10 moles %. The size of the liposomes (about 
80 nm) means that they have a long circulating half-life and a 
good penetration into tissues. The stable bilayer composition 
should reduce exchanges with lipoproteins and contribute to 
the very low toxicity of this formulation (Adler-Moore and 
Profﬁ  tt 2002).
Amphotec® (Amphocil™ in Europe and Amphotec® in the 
US) is composed of complexes between cholesteryl sulfate 
and AMB in equimolar proportions. These have the form of 
thin discs of about 120 nm in diameter. However, despite 
the small size, their circulation time is much less than that 
of AmBisome® and they deliver AMB rapidly to phagocytic 
cells (Guo 2001).
Abelcet® is composed of two synthetic phospholipids 
– dimyristoyl phosphatidylcholine and  dimyristoyl phos-
Table 1 Commercial formulations of AMB
Name Composition  AMB/lipid  Charge  Form  Size  (μm) Reference 
   (mol%)      
AmBisome®  Hydrogenated soy   10  Negative  Small unilamellar   0.08  Adler-Moore 
  phosphatidylcholine:cholesterol:       liposomes    and Profﬁ  tt 
 distearoylphosphatidylcholine:    AMB          2002
   2:1:0.8:0.4         
Amphotec®  Cholestryl sulfate:  AMB  50  Negative  Disc-like complexes  0.12  Guo 2001
(Amphocil®) 1:1         
Abelcet®  Dimyristoylphosphatidylcholine:   50  Negative  Ribbon-like complexes  1–10  Janoff et al 
 Dimyristoylphosphatidylglycerol:            1993
 AMB         
 7:3:10         International Journal of Nanomedicine 2007:2(3) 304
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phatidylglycerol in a 7 to 3 molar ratio with an equimolar 
amount of AMB. These components assemble in ribbons 
of 1 to 10 micrometers in length. These larger objects are 
rapidly accumulated in the mononuclear phagocyte system 
(Janoff et al 1993).
Clinical studies in fungal infections
Systemic fungal infections, dominated by Candida and 
Aspergillus infections, remain the leading cause of infec-
tion-related mortality and morbidity in many populations 
of immunocompromised patients. Azoles are often recom-
mended for Candida infection but the epidemiology of 
Candida infection has changed over the last few years. 
C albicans now comprises less than half of the isolates of 
candidemia worldwide (Eggimann et al 2003; Pappas et al 
2003). The other half is represented by a variety of non-albi-
cans species, for some of which the susceptibility to azoles, 
particularly ﬂ  uconazole, is decreased. For Aspergillus and 
other less common moulds, the mortality rates are greater 
than 60% and even higher in patients with disseminated in-
fection, although the extended-spectrum azoles represent a 
major advance as a ﬁ  rst-line treatment (Herbrecht et al 2002). 
Therefore, there is a need for more effective antifungal drugs 
with a wide spectrum.
In this respect, AMB has the advantage of covering most 
of the fungal pathogens involved in human disease. However, 
the use of AMB formulated with deoxycholate (Fungizone®) 
has been limited by infusion-related side effects and cumula-
tive nephrotoxicity which, in ﬁ  ne, actually increase overall 
healthcare expenses, despite its primarily low cost (Maertens 
et al 2001). For these reasons, and because other alterna-
tives are now available, primary therapy with Fungizone® 
is more and more challenged by new antifungal therapies 
for use in many systemic mycoses, including moulds, such 
as Aspergillus. These new antifungal therapies include 
extended-spectrum triazoles, the echinocandins, and also 
lipid formulations of AMB, as described above (Herbrecht 
et al 2003). Among the lipophilic formulations of AMB 
commercially available, the majority of studies have been 
carried out with liposomal AMB (AmBisome®).
Clinical efﬁ  cacy of liposomal AMB
Due to the paucity of diagnostic means for fungal infections and 
the poor prognosis of full-blown invasive fungal infections, clini-
cians use several strategies when faced with fungal infections. 
Antifungal drugs are given for demonstrated infections but in 
high-risk patients, they may be administered empirically, in the 
case of persistent fever despite appropriate antibacterials, or as 
prophylaxis, in every patient at risk of fungal infection whatever 
the clinical signs. The efﬁ  cacy of liposomal AMB has been 
studied in these different settings, both in open and randomized 
studies. Liposomal AMB has also proved effective in the treat-
ment of visceral leishmaniasis (see below).
Demonstrated infections
In full-blown fungal infections, initial open studies involving 
patients refractory to, or intolerant of, Fungizone® showed 
improvement or cure in 66% and 81% of patients with inva-
sive aspergillosis and invasive candidiasis respectively, with 
the liposomal form (Ringden et al 1991). Two studies have 
suggested a superior efﬁ  cacy of liposomal AMB compared to 
Fungizone® in probable or proven fungal invasive infections 
but were insufﬁ  cient to give a deﬁ  nitive answer (Leenders 
et al 1997; Leenders et al 1998).
Another important issue is the dose to be adminis-
tered. It was expected that the good tolerance profile 
would allow high liposomal AMB doses to be given and 
achieve better efficacy without increasing toxicity. In 
a randomized trial comparing two doses of liposomal 
AMB (1 versus 4mg/kg/day) for the primary treatment 
of invasive aspergillosis, an overall response rate of 55% 
was observed, regardless of the dose, with no difference 
in either arm (Ellis et al 1998). This substantial response 
rate demonstrates evidence of the efficacy of liposomal 
AMB in first-line therapy of invasive aspergillosis. To 
determine the appropriate daily dose for the initial treat-
ment of invasive aspergillosis and other filamentous fun-
gal infections in immunocompromised patients, a phase 
3, multi-center, randomized, double-blind study of the 
safety and efficacy of an liposomal AMB loading dose 
regimen versus a standard liposomal AMB regimen was 
performed (Cornely 2005). The study compared a load-
ing regimen of 10 mg/kg/day × 14d versus the standard 
regimen of 3 mg/kg/day for 14 days. The standard regi-
men had a favorable overall response rate of 50% and a 
12-week survival rate of 72% comparable to those previ-
ously reported for voriconazole in a similarly designed 
trial (Herbrecht et al 2002). However, the high-dose 
regimen did not demonstrate any improvement in overall 
response or survival.
In an attempt to sum up the efﬁ  cacy of lipid formulations of 
AMB, not all in the liposomal form, a meta-analysis of seven 
randomized studies was performed (Barrett et al 2003). This 
analysis did not show any difference in the response rate between 
the lipid formulations of AMB and Fungizone® but showed a 
decrease in mortality (OR = 0.72; 95% CI = 0.54 – 0.97).International Journal of Nanomedicine 2007:2(3) 305
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The poor outcome of mould infections and the availability 
of several antifungal drugs of different classes have stimulated 
the evaluation of alternatives based on combinations of different 
antifungal drugs (Johnson et al 2004). Apart from the association 
of Fungizone® and 5-ﬂ  uorocytosine which has been the recom-
mended treatment for cryptococcal meningitis for a long time, 
the other associations, mainly between Fungizone® and azoles, 
raised several concerns about possible toxicities (Polak 1999). In 
vivo studies have shown encouraging results, for the associations 
of liposomal AMB with both voriconazole and echinocandins 
in models as different as rat models of invasive aspergillosis 
(Kirkpatrick et al 2006), a murine model of cerebral aspergillosis 
(Clemons et al 2005), or a murine model of C. glabrata systemic 
infection (Olson et al 2005). In humans, a few case reports and 
small series of beneﬁ  c results of associations have been reported 
but none are randomized studies (Aliff et al 2003; Kontoyiannis 
et al 2003; Marr et al 2004).
Empirical therapy
In the setting of empirical therapy for persistent febrile 
neutropenia, comparative studies concluded that liposomal 
AMB is as effective as Fungizone® (Prentice et al 1997; 
Walsh et al 1999). A double-blind study compared the 
safety of liposomal AMB (3 or 5 mg/kg/day) and AMB lipid 
complex (5 mg/kg/day) (Wingard et al 2000). Neither of the 
two liposomal AMB dosages yielded a better outcome than 
AMB lipid complex.
Primary prophylaxis
Three randomized trials have assessed the efﬁ  cacy of low 
doses of liposomal AMB as prophylaxis in bone marrow 
transplant recipients, without demonstrating any beneﬁ  t 
(Kelsey et al 1999; Tollemar et al 1993a, 1993b). One study 
in liver transplant patients showed a signiﬁ  cant decrease in 
invasive Candida spp. infections in the liposome-treated 
patients, compared to the placebo-treated patients but the 
1-month survival was identical in both groups. However, 
long-term survival was increased in patients who received 
liposomal AMB (Tollemar et al 1995). Recently, a pharma-
cokinetic study of once-weekly high-dose liposomal AMB 
as fungal prophylaxis for immunocompromised children 
undergoing stem cell transplantation suggested that this dos-
age may provide useful protection against fungal infections 
(Mehta et al 2006).
Tolerability
Patients treated with liposomal AMB at 3 mg/kg/day had less 
infusion-related adverse events, needed less premedication, 
and had less nephrotoxicity than patients treated with Fun-
gizone® at 0.6 mg/kg/day (Prentice et al 1997; Walsh et al 
1999). The tolerability of high doses up to 7.5–15 mg/kg/day 
appeared satisfactory (Walsh et al 2001). These results justi-
ﬁ  ed comparing a liposomal AMB loading dose regimen versus 
a standard liposomal AMB regimen (Cornely 2005). Higher 
rates of hypokalemia and nephrotoxicity were seen compared 
with the standard dose regimen with no better efﬁ  cacy. In 
neonates, high doses (5–7 mg/kg/day) of liposomal AMB 
for a median of 18 days seem to be much better tolerated 
than in adults (Juster-Reicher et al 2003). Compared with 
AmB lipid complex at 5 mg/kg/day, liposomal AMB at 3 
and 5 mg/kg/day showed less infusion-related reactions and 
nephrotoxicity in febrile neutropenic patients (Wingard et al 
2000). This study clearly indicates that liposomal AMB was 
better tolerated than AMB lipid complex.
Conclusion
Liposomal AMB has been shown to be at least as efﬁ  cacious 
as Fungizone® and has a dramatically improved safety pro-
ﬁ  le compared with the traditional form. The recommended 
dose is 3–5mg/kg/day for demonstrated fungal infection 
and 3 mg/kg/day for empirical therapy, and doses up to 3 
mg/kg/day of liposomal AMB are well tolerated. Higher 
doses have not shown any therapeutic beneﬁ  t in invasive 
aspergillosis whereas they increased renal toxicity. For 
some rare ﬁ  lamentous fungus infections such as those due 
to zygomycetes and Fusarium spp, the liposomal formula-
tion may be considered as ﬁ  rst-line therapy because of the 
absence of an effective alternative, although new azoles may 
be effective towards some of these fungi. The in vitro models 
and the experimental data in animals show that combination 
therapy may improve outcome, but these experimental results 
remain to be conﬁ  rmed with clinical trials.
Lipid formulations of AMB
in the treatment of leishmaniasis
Leishmaniasis is a family of protozoal infections transmitted 
by sand-ﬂ  y bites, which affects about 12 million people in 
warm regions throughout the world. Visceral leishmani-
asis, in which the parasite – Leishmania donovani in India 
and Bangladesh, L. infantum in the rest of Asia, Africa and 
Europe and L. chagasi in the Americas – develops within 
tissue macrophages in the liver, spleen and bone marrow, is 
the most serious manifestation (Herwaldt 1999). It is endemic 
in India, Bangladesh and Sudan where it represents a major 
public health problem and is also becoming increasingly 
prevalent as an opportunistic infection in Western countries, International Journal of Nanomedicine 2007:2(3) 306
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among individuals who are infected with the HIV virus or 
are immunocompromised for other reasons. Cutaneous leish-
maniasis, characterized by skin lesions, is more common but 
less serious. Muco-cutaneous and disseminated cutaneous 
manifestations also occur (Herwaldt 1999). Early treatment 
options were pentavalent antimonials and pentamidine, which 
have shown problems of toxicity and resistance (Murray, 
2001). AMB was found to be an effective treatment for 
visceral leishmaniasis in the 1990s (Murray 2004; Singh 
and Sivakumar 2004). Lipid formulations of AMB are a 
particularly attractive alternative in this context because 
they are accumulated in the same cells as the parasite. Thus 
AmBisome® was approved by the FDA in 1997 (Meyerhoff 
1999). Despite the reduced toxicity of the lipid formula-
tions, their high cost is prohibitive in the zones in which 
visceral leishmaniasis is endemic. A comparative study by 
Sundar et al (2004) showed that although the higher doses 
that could be given with the lipid formulations reduced the 
total time for cure and therefore the cost of hospitalization, 
this only partly offset the high purchase price of the drug. 
On the other hand, in a European situation, when cost is not 
such a preponderant issue, lipid formulations of AMB have 
become the treatment of choice (Gradoni et al 2004).
Cutaneous leishmaniais can also be treated effectively 
with lipid formulations of AMB (Amato et al 2004, Yardley 
and Croft 2000). In this case, the smaller formulations 
(AmBisome®, Amphocil™) are the most effective, because 
of their small size.
Recently, a new drug, miltefosine (hexadecylphospho-
choline) has been shown to be effective against visceral 
leishmaniasis by the oral route (Murray 2001; Sundar et al 
2002). This is a deﬁ  nite breakthrough and shows an obvious 
advantage over the current formulations of AMB, which 
are administered intravenously. Associations of AMB and 
miltefosine may have some therapeutic advantage (Seifert 
and Croft 2006).
Other formulations of AMB and 
new trends in their administration
Lipid-based formulations
An adhoc solution to the problem of AMB toxicity is to mix 
Fungizone® with Intralipid®, a preparation for parenteral 
nutrition, which consists of an oil-in-water emulsion sta-
bilized with lecithin. The AMB is complexed by the phos-
pholipids on the surface of the oil globules and its toxicity 
is reduced compared with Fungizone® alone. However, this 
method does not give reproducible results (Tomii 2002).
More recently, AMB has also been mixed with another 
proprietary lipid emulsion formulation, Lipofundin®. AMB 
was added as a powder, and the use of a high-pressure 
homogenizer promoted its dissolution in the interfacial layer, 
according to the patented SolEmuls® technology. However, 
no toxicity data are available for this formulation (Müller 
et al 2004).
De novo emulsion formulations of AMB have also been 
described, for example, those studied by Egito and collabora-
tors (1996a). The emulsion form reduced the toxicity of AMB 
considerably, compared with Fungizone®, although less than 
AmBisome®, and allowed higher doses to be given, allow-
ing a better cure rate of infections with Candida albicans. 
Circular dichroism studies showed that the AMB remained 
in the monomeric form within the emulsions, over a wide 
range of dilutions (Egito et al 1996b).
Seki and co-workers have formulated AMB into nano-
sized emulsions called “Lipid Nano Spheres” which attempt 
to imitate lipoproteins. These small particles (25–50 nm) 
reduced AMB toxicity compared with Fungizone®, and showed 
similar activity against Candida albicans. Like AmBisome®, 
these small particles showed reduced uptake by macrophages 
and persistence in the circulation (Fukui et al 2003).
Heat-treatment of AMB is a simple method of reduc-
ing toxicity. Heating the Fungizone® formulation to 70° C 
provokes the formation of superaggregates, as detected by 
spectrophotometric methods, rather than aggregates, which 
are less toxic to mammalian cells while retaining almost 
equivalent antifungal activity (Gaboriau et al 1997). Cryo-
transmission electron microscopy revealed that while the 
native product was composed mainly of micelles of about 
4 nm in diameter, with some threadlike aggregated micelles, 
the heated formulation contained much larger networks of 
about 300 nm (van Etten et al 2000).
Another approach to modulating the solubility, and 
therefore the toxicity of AMB was the use of ions from 
the Hofmeister series which alter water properties. While 
kosmotropes increased AMB aggregation, the chaotrophic 
ions thiocyanate and trichloroacetate were found to allow 
solubilization of AMB as monomers (Grijalba et al 2006).
Larabi et al developed a lipid complex system with a 
similar composition to Abelcet®, but prepared by a different 
method known as nanoprecipitation. This led to the forma-
tion of thin discs of about 250 nm in diameter, in which the 
lipids were probably in an interdigitated form rather than a 
bilayer (Larabi et al 2004a). This change in size and mor-
phology reduced the toxicity, both towards macrophages in 
vitro and in vivo after both acute and chronic administration International Journal of Nanomedicine 2007:2(3) 307
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to mice, compared to both Fungizone® and Abelcet® (Larabi 
et al 2003, Larabi et al 2004b). The activity of the complexes 
against visceral leishmaniasis in mice was higher than that 
of Abelcet® but not as high as that of AmBisome® (Larabi 
et al 2003). This illustrates the importance of nanosystem 
morphology in determining the biological effect.
Another disc-like formulation was developed by Lincopan 
et al (2005, 2006) using the cationic lipid dioctadecyldimeth-
ylammonium bromide (DODAB). This lipid formed bilayer 
fragments of about 65 nm in diameter with AMB at a low 
drug-to-lipid ratio. This formulation reduced nephrotoxicity 
and hepatotoxicity compared with Fungizone®, but spleen 
toxicity due to the cationic lipid was observed. At higher 
drug-to-lipid ratios, drug particles surrounded by a lipid 
bilayer are formed. The toxicity and therapeutic activity of 
these formulations have not yet been investigated.
Another group (Oda et al 2006) has tried to imitate 
lipoprotein particles as an original delivery system for AMB. 
The speciﬁ  c apolipoprotein from high density lipoprotein, 
ApoA-I, was added to mixtures of dimyristoylphosphatidyl-
choline, dimyristoylphosphatidylglycerol and AMB. After 
sonication and dialysis, a limpid preparation was obtained, 
consisting of disc-like particles of 8–10 nm in diameter. The 
circular dichroism spectra indicated that AMB was associ-
ated with lipid in the formulation. This preparation had much 
lower toxicity than Fungizone® in vitro and in vivo, which 
allowed higher doses to be given to mice, leading to effective 
treatment of Candida albicans infection. These systems also 
showed a good activity against Leishmania major in Balb/C 
mice, although no comparison with any other formulation 
was made (Nelson et al 2006).
Lipid cochleates are an interesting system for delivering 
AMB. These are formed mainly from phosphatidylserine 
and calcium, which associate by electrostatic interaction to 
form cylindrical structures consisting of a rolled-up bilayer. 
They are particularly appropriate for entrapping small hy-
drophobic or amphiphilic molecules like AMB (Zarif 2005). 
Like other lipid-based systems, AMB cochleates reduce the 
toxicity of the antibiotic. They are effective against murine 
candidasis and aspergillosis after i.p. and oral administration 
(Santangelo et al 2000; Delmas et al 2002).
Polymer-based formulations
AMB has been conjugated to a number of macromolecules 
with the aim of improving its solubility. Many of these have 
been derived from polysaccharides. For example, AMB has 
been conjugated to arabinogalactan (Ehrenfreund-Kleinman 
et al 2002). Polymers of about 30 kDa with about 20% of 
AMB by weight were obtained. The maximum tolerated 
dose of AMB was greatly increased by conjugation, while 
the antifungal activity against Candida albicans remained 
comparable to that of Fungizone®. A similar approach used 
dextran as the polysaccharide carrier. In particular, the prepa-
ration of a conjugate in which the free aldehyde groups were 
blocked showed very low toxicity towards mammalian cells 
while conserving antiparasitic activity (Sokolsky-Papkov 
et al 2006). AMB has also been conjugated to poly (ethylene 
glycol) (PEG). Attachment of AMB to a PEG of 40 kDa led 
to a highly water-soluble product which was only hydro-
lyzed slowly in rat plasma. It was 6 times less toxic than 
Fungizone® in rats and showed equal or superior antifungal 
activity (Conover et al 2003).
A number of groups have incorporated AMB into 
micelles prepared from amphiphilic polymers. Diblock 
copolymers consisting of poly (ethylene oxide) and poly 
(aspartic acid) substituted with various hydrophobic groups 
have been extensively studied in the laboratory of Kwon. 
In particular, poly (ethylene oxide)-block-poly (N-hexyl-L-
aspartamide)-stearic acid ester micelles allow the antibiotic 
to be incorporated in its non aggregated form, as shown by 
spectrophotometric measurements and to be released in a 
sustained fashion. Such micelles show similar activity to 
Fungizone® in a mouse model of disseminated candidiasis 
(Adams and Kwon 2004). A similar system based on par-
tially benzylated poly (aspartic acid) without a PEG block 
has been investigated by Yoo et al (2006). This polymer 
formed “nanoparticular” micelles of 20 nm in diameter, 
in which AMB aggregation was reduced compared with 
Fungizone®, as judged by its spectral properties. The acute 
toxicity in mice was reduced, as was damage to kidney 
cells after intravenous administration to rats, while the in 
vitro activity against Candida albicans was similar to that 
of Fungizone®. Vandermeulan et al (2006) have used poly 
(ethylene glycol)-block-poly (ε-caprolactone-co-trimethyl-
enecarbonate) micelles to encapsulate AMB. These micelles 
are easy to prepare and although they reduce the antifungal 
activity they also reduce the amount of hemolysis.
There have been a few reports of nanoparticulate forms 
of AMB. A study by Venier-Julienne et al (1995) used 
AMB incorporated into poly (D, L-lactide-co-glycolide) 
nanoparticles. When their activity was tested against cul-
tures of promastigotes of L. donovani within peritoneal 
macrophages, unloaded nanoparticles had a high an effect 
as loaded ones. This could be attributed to reactive oxygen 
intermediate generation following phagocytosis of the 
nanoparticles.International Journal of Nanomedicine 2007:2(3) 308
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Espuelas et al attempted to incorporate AMB into 
poly (ε-caprolactone) nanoparticles (Espuelas et al 1998a; 
Espuelas et al 1998b). In fact, AMB was adsorbed onto 
the surface of the particles and was released on dilution, 
but despite this limitation, the acute toxicity of AMB in 
mice was reduced compared with Fungizone® (Espuelas 
et al 1997). During this work, it was noted that AMB also 
formed mixed micelles with the poloxamer 188 surfactant 
used to stabilize the nanoparticles (Espuelas et al 1998b). 
These micelles were found to have activity against clinical 
isolates of Candida albicans in vitro and also, interestingly, 
to reverse the resistance of Leishmania donovani parasites 
which had been rendered resistant to the drug by in vitro 
pressure, by a synergistic effect of AMB and the poloxamer 
(Espuelas et al 2000). However, the results obtained with 
Candida albicans-infected macrophages and in mice were 
disappointing, since the LD50 was increased compared with 
Fungizone® (Espuelas et al 2003).
More recently, AMB was incorporated into nanoparticles 
formed by a complex of two polysaccharides of opposing 
charge: chitosan and dextran sulfate. A high encapsulation 
rate for AMB was obtained, but spectral analysis showed 
that it was aggregated. A reduction in renal toxicity was 
observed but the large size of these particles (600–800 nm) 
suggests that they would only be useful for liver delivery 
(Tiyaboonchai et al 2006).
Microsphere formulations of AMB have also been 
tested for therapy of leishmaniasis. Albumin microspheres 
reduced the toxicity and increased the therapeutic efﬁ  ciency 
of AMB against Leishmania infantum in hamsters. As might 
be expected, the microparticulate form increased drug 
accumulation in the liver and spleen (Sanchez-Brunete et al 
2004). High doses of AMB administered in these particles 
deactivated expression of anti-inﬂ  ammatory cytokines and 
increased pro-inﬂ  ammatory ones, which probably contrib-
uted to the therapeutic effect (Rama Iniguez et al 2006). 
Different microsphere formulations were tested (Sanchez-
Brunete et al 2005). Poly (lactide-co-glycolide) and poly-
anhydride microspheres were less effective than albumin 
ones in reducing liver and spleen parasite load, and albumin 
microspheres also induced a signiﬁ  cant antibody response 
to parasite antigens.
Carbon nanotubes (CNT) have been attracting much 
attention lately as potential drug delivery systems. AMB has 
been linked covalently to functionalized CNT at the same 
time as ﬂ  uorescein and uptake of the resulting particles into 
Jurkat cells was demonstrated (Wu et al 2005). Interestingly, 
the minimal inhibitory concentrations for several fungal spe-
cies were reduced by this association, while “empty” CNT 
were without effect.
Administration of AMB by other routes: 
oral and pulmonary
One major disadvantage of AMB is its very low bioavail-
ability by the oral route. This is essentially due to its very 
low solubility in aqueous media and its relatively high 
molecular weight (Dangi et al 1998). A number of different 
lipid-based systems have been used in attempts to improve 
the intestinal absorption of AMB. The presentation of the 
drug in the monomeric form could be expected to facilitate 
its dissolution and other components of the formulations may 
have absorption promoting effects.
Thus, ternary mixed micelle systems of AMB, deoxycho-
late and oleic acid, monoolein or soy lecithin were found to 
enhance the permeability of AMB in isolated intestinal loops 
(Dangi et al 1998). These systems have not been tested in 
vivo, however. Another system in which AMB was mixed 
with Peceol, a glyceride-rich vehicle for oral administration, 
also gave promising results, increasing lymphatic transport of 
AMB after oral administration to rats (Risovic et al 2004).
AMB cochleates (see above) have also proved to be efﬁ  -
cient in the treatment of fungal infections by the oral route. In 
a model of Balb/C mice infected with Candida albicans, oral 
administration of these lipid particles was able to eradicate 
the infection from the lungs and prolong survival as effec-
tively as Fungizone® given i.p. at a similar dose (Santangelo 
et al 2000). Efﬁ  cacy was also demonstrated in a murine model 
of systemic aspergillosis (Delmas et al 2002).
Recently, AMB was associated with another lipidic anti-
leishmanial agent, miltefosine (hexadecylphosphocholine or 
HePC). As described above, this molecule has been shown to 
be active by the oral route (Murray 2001; Sundar et al 2002) 
and has the interesting property of opening tight junctions 
in the Caco2 intestinal cell model (Ménez et al 2006a). Its 
alkylphospholipid structure suggested that it might be able to 
associate with AMB and in fact, spectroscopic studies showed 
that this can be the case (Ménez et al 2006b). However, rather 
than promoting absorption of AMB, the association led to a 
reduction of both cellular uptake and transepithelial transport 
in the Caco2 model (Ménez et al 2006b).
Kayser et al (2003) formulated a nanosuspension of 
AMB for administration by the oral route. The particles were 
prepared by high pressure homogenization of the drug with 
a mixture of surfactants. A reduction in parasite load in the 
liver was observed when the formulation was administered 
orally to mice infected with Leishmania donovani. This result International Journal of Nanomedicine 2007:2(3) 309
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may be related to the presence in the formulation of Tween 
80®, which is known to promote passage across biological 
membranes.
Pulmonary infections with Aspergillus spp. are a major 
clinical problem in immunocompromised patients. In conse-
quence, there has been much interest in the use of aerosolized 
AMB formulations for treatment, and for prophylaxis in 
patients undergoing transplant surgery (Drew 2006). Animal 
studies have shown that liposomal formulations lead to higher 
concentrations of AMB in the lungs than Fungizone® (Ruij-
grok et al 2000) or AMB directly solubilized in ﬂ  uorocarbons 
(Vyas et al 2005). Clinical trials have shown that the lipid 
formulations are easier to aerosolize and better tolerated than 
Fungizone® (Perfect et al 2004; Drew 2006).
Speciﬁ  c targeting of AMB-loaded 
nanosystems
The studies described above have mainly taken advantage of 
the uptake of colloidal particles by the mononuclear phago-
cyte system and thus reach micro-organisms within these 
cells, or on the small size (for example AmBisome®) and 
surface properties which allow the carriers to remain in the 
circulation and reach other tissues in a non speciﬁ  c function. 
However, there are a few reports of attempts to deliver AMB 
to particular sites using nanosystems bearing speciﬁ  c target-
ing ligands. The ligands used have been sugars, antibodies or 
small peptides, as described in the following paragraphs.
Although the “natural” target of colloidal drug carriers is 
phagocytic cells, their uptake by macrophage, and particu-
larly the Küpffer cells of the liver, can be greatly increased 
by modifying the surface with mannose residues which are 
recognized by the mannose-fucose receptor on these cells 
(Barratt and Schuber 1993). This strategy has been applied to 
the delivery of AMB to macrophages for treatment of leish-
manias (Vyas et al 2000).  Similarly, liposomes loaded with 
AMB and coated with mannan or pullanan, a glucose-con-
taining polysaccharide have been administered to rats as an 
aerosol to target alveolar macrophages. Drug concentrations 
were higher than those delivered by unmodiﬁ  ed liposomes 
and were sustained for 24h (Vyas et al 2005).
Galactose receptors are expressed by liver cells and some 
micro-organisms. Polylactide microspheres containing AMB 
have been functionalized with galactose residues and have 
been shown to bind to Kluyveromyces bulgaricus yeast cells 
(Kassab et al 2002). Heparin is a negatively charged polysac-
charide with many interesting biological properties, including 
bioadhesion. Clemons et al (2001) encapsulated AMB within 
small (105 nm) hydrophilic nanoparticles bearing heparin 
at their surface. Their retention in the lungs was increased 
compared with Fungizone®, leading to a better therapeutic 
index against pulmonary blastomycosis in mice.
The coupling of antibodies to the surface of a liposome 
can theoretically give a delivery system targeted to a speciﬁ  c 
cell type. Small liposomes bearing a monoclonal antibody 
to Cryptococcus neoformans bound speciﬁ  cally to the yeast 
and, when administered intravenously to infected mice, 
prolonged survival longer than AMB in solution in dimethyl-
sulfoxide/phosphate-buffered saline, non-targeted liposomes 
or liposomes targeted with an irrelevant antibody (Dromer 
et al 1990). However, antibody-bearing systems will still be 
accumulated within mononuclear phagocytes unless their 
surface is modiﬁ  ed to avoid opsonization. Thus, the concept 
of sterically stabilized liposomes has emerged, in which the 
surface is covered with end-grafted PEG chains. Targeting 
can be achieved by coupling the antibody or other ligand to 
the distal end of a proportion of these chains (Mercadal et al 
1999). Thus, sterically stabilized liposomes containing AMB 
and bearing an antibody speciﬁ  c for pulmonary endothelium 
at the end of the PEG chains have been prepared (Otsubo 
et al 1998). Accumulation of antibiotic in the lungs was ob-
served, as opposed to its remaining in the blood in the case 
of non-targeted PEG-bearing liposomes or accumulating in 
the liver in the case of conventional liposomes. This was 
accompanied by increased efﬁ  cacy against experimental 
aspergillosis in mice.
One smaller ligand which has been to direct AMB-loaded 
liposomes is the tetrapeptide tuftsin (Thr-Lys-Pro-Arg, 
Agrawal et al 2002), which binds to a speciﬁ  c receptor on 
macrophages. This peptide has the advantage of being both 
a targeting element promoting liver accumulation and a mac-
rophage activator. The anti-leishmanial activity of the drug is 
thus reinforced by macrophage-mediated effects. Zhang et al 
(2003) have used a targeting strategy to deliver AMB across 
the blood-brain barrier. A peptide analogue of bradykinin, 
RMP-7, was coupled to PEG on sterically stabilized lipo-
somes. This peptide interacts with the B2 receptor on brain 
capillary endothelial cells and increases the permeability of 
the vessels. By this means, AMB accumulation in the brain 
can be improved.
Conclusion
AMB is a good example of how an appropriate delivery 
system can improve the therapeutic index of a drug. The 
advantage of the commercial lipid-based formulations is 
principally that they reduce toxicity compared with the con-
ventional formulation, allowing higher doses to be given. A International Journal of Nanomedicine 2007:2(3) 310
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disadvantage is the high cost of these formulations, particu-
larly with respect to their activity against parasitic diseases. 
Kleinberg (2006) has attempted to review the cost-effective-
ness of these formulations compared with Fungizone®, taking 
into account all factors such as the time of hospitalization, in 
a North American setting, and concluded that in many cases, 
for example in the opportunistic infections in cancer patients, 
lipid formulations are a better choice than the conventional 
formulation. However, the cost of these formulations remains 
prohibitively high for the treatment of leishmaniasis in 
endemic areas (Sundar et al 2004).
Another disadvantage of AMB for mass treatment is 
its very low bioavailability by the oral route. Some studies 
reported above suggest that the use of nanosized formula-
tions based on lipids or other amphiphilic molecules could 
be useful in overcoming this problem. Similarly, the deliv-
ery of drugs by the pulmonary route to combat respiratory 
infections is attracting much attention at the moment. New 
formulations of AMB could contribute in this area by increas-
ing tolerability and ensuring delivery to the appropriate part 
of the lung. Another non parenteral route for which new 
AMB formulations could provide a therapeutic advance is 
in the eye, for example, in the treatment of fungal keratitis. 
Liposomal formulations have shown some advantages by 
this route, by reducing irritation and prolonging the residence 
time of drugs (Bochot et al 2000).
Finally, progress in the design of drug delivery systems 
has led to the development of carriers targeted to speciﬁ  c 
tissues and cells. Such technology applied to AMB would 
lead to a further increase in its therapeutic index. Therefore, 
as a result of innovative formulations, after almost 50 years 
on the market, AMB remains an extremely useful drug.
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